Polyrizon completes fourth and fifth U.S. site contracts for NASARIX allergy study
Polyrizon said it has completed contracting for the fourth and fifth U.S. clinical sites for NASARIX™ first-in-human allergy study, completing all five U.S. site contracts for the trial.
Raanana, Israel, Sept.
02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
NASDAQ:PLRZ (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clini…